Pharmacokinetic Interaction of a Four-Drug Combination Therapy for Treating Mycobacterium abscessus Complex Infection: A Phase I Clinical Trial

Clofazimine (CFZ) is a therapeutic option for pulmonary nontuberculous mycobacterial (NTM) infections; however, knowledge on its pharmacokinetics and drug–drug interactions remains limited. This study evaluated the pharmacokinetics and adverse events associated with concomitant administration of CFZ, clarithromycin (CAM), amikacin (AMK), and imipenem (IPM) in patients with pulmonary Mycobacterium abscessus complex (MABC) disease. Patients diagnosed with pulmonary MABC were treated with combined CFZ, CAM, AMK, and IPM. Serum drug concentrations were measured on days 1 and 13 using liquid chromatography–tandem mass spectrometry. Pharmacokinetic parameters were calculated using a noncompartmental analysis model, and their relationship with adverse events (AEs) was evaluated. Ten patients participated with a mean age of 65.5 years (49–74 years). Both CFZ and CAM exhibited significant accumulation by day 13 compared with day 1, whereas AMK and IPM showed no notable pharmacokinetic changes. Patients who experienced nausea and vomiting had significantly higher CFZ trough levels, CAM area under the serum concentration–time curve to the last quantifiable concentration (AUC last ), and IPM AUC last than those without these symptoms. One case exhibited QT interval prolongation; however, no association with plasma drug concentrations was identified. CAM, which typically does not accumulate with monotherapy, showed approximately twofold accumulation when co-administered with CFZ, indicating a potential pharmacokinetic drug–drug interaction between these drugs.

Authors

Institutions

Publication Details

Journal
European Journal of Drug Metabolism and Pharmacokinetics
Published
2026-11-14
DOI
https://doi.org/10.1007/s13318-026-01046-6
Primary Topic
Mycobacterium research and diagnosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacokinetic Interaction of a Four-Drug Combination Therapy for Treating Mycobacterium abscessus Complex Infection: A Phase I Clinical Trial

Yuki Enoki, Ho Namkoong, 由美子 藤井, Masanori Kaji et al.
European Journal of Drug Metabolism and Pharmacokinetics
Mycobacterium research and diagnosis
article

Pharmacokinetic Interaction of a Four-Drug Combination Therapy for Treating Mycobacterium abscessus Complex Infection: A Phase I Clinical Trial

Yuki Enoki, Ho Namkoong, 由美子 藤井, Masanori Kaji, Kengo Nagashima, Shuhei Azekawa, Naoki Fukunaga, Naoki Miyazaki, Yuki Igarashi, Kensuke Nakagawara, Noriyuki Ishida, Shiho Suzuki, Koichi Fukunaga, Kazuaki Matsumoto, Yasuyuki Tokuhiro, Yukiko Matsushima, Takanori Asakura, Naoki Hasegawa, Genta Nagao, Kazuma Yagi, Chika Asami, Atsuho Morita, Hiromu Tanaka, Fumika Kano
article en

Abstract

Clofazimine (CFZ) is a therapeutic option for pulmonary nontuberculous mycobacterial (NTM) infections; however, knowledge on its pharmacokinetics and drug–drug interactions remains limited. This study evaluated the pharmacokinetics and adverse events associated with concomitant administration of CFZ, clarithromycin (CAM), amikacin (AMK), and imipenem (IPM) in patients with pulmonary Mycobacterium abscessus complex (MABC) disease. Patients diagnosed with pulmonary MABC were treated with combined CFZ, CAM, AMK, and IPM. Serum drug concentrations were measured on days 1 and 13 using liquid chromatography–tandem mass spectrometry. Pharmacokinetic parameters were calculated using a noncompartmental analysis model, and their relationship with adverse events (AEs) was evaluated. Ten patients participated with a mean age of 65.5 years (49–74 years). Both CFZ and CAM exhibited significant accumulation by day 13 compared with day 1, whereas AMK and IPM showed no notable pharmacokinetic changes. Patients who experienced nausea and vomiting had significantly higher CFZ trough levels, CAM area under the serum concentration–time curve to the last quantifiable concentration (AUC last ), and IPM AUC last than those without these symptoms. One case exhibited QT interval prolongation; however, no association with plasma drug concentrations was identified. CAM, which typically does not accumulate with monotherapy, showed approximately twofold accumulation when co-administered with CFZ, indicating a potential pharmacokinetic drug–drug interaction between these drugs.

European Journal of Drug Metabolism and Pharmacokinetics
Keio University (JP), Keio University Hospital (JP)
Mycobacterium research and diagnosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon